Foresight Global Investors Inc. Invests $1.16 Million in Kenvue Inc. (NYSE:KVUE)

Foresight Global Investors Inc. acquired a new stake in Kenvue Inc. (NYSE:KVUE) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 53,750 shares of the company’s stock, valued at approximately $1,157,000.

Several other institutional investors and hedge funds have also recently modified their holdings of KVUE. Clearstead Advisors LLC acquired a new position in shares of Kenvue in the third quarter worth $25,000. Planned Solutions Inc. acquired a new stake in Kenvue in the 4th quarter valued at about $27,000. Venturi Wealth Management LLC purchased a new position in shares of Kenvue in the 3rd quarter valued at about $28,000. EverSource Wealth Advisors LLC acquired a new position in shares of Kenvue during the third quarter worth about $28,000. Finally, Pacific Capital Wealth Advisors Inc. purchased a new stake in shares of Kenvue during the fourth quarter worth approximately $28,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Stock Up 0.4 %

Kenvue stock traded up $0.09 during mid-day trading on Thursday, reaching $20.54. 13,146,930 shares of the company were exchanged, compared to its average volume of 17,092,076. The company has a quick ratio of 0.78, a current ratio of 1.12 and a debt-to-equity ratio of 0.69. The firm’s 50-day simple moving average is $19.90 and its two-hundred day simple moving average is $20.12. Kenvue Inc. has a twelve month low of $17.82 and a twelve month high of $27.80.

Kenvue (NYSE:KVUE) last issued its earnings results on Tuesday, May 7th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.25 by $0.03. The business had revenue of $2.89 billion for the quarter, compared to the consensus estimate of $3.79 billion. Kenvue had a net margin of 9.87% and a return on equity of 15.62%. The company’s revenue was down 24.9% on a year-over-year basis. Research analysts forecast that Kenvue Inc. will post 1.15 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 22nd. Investors of record on Wednesday, May 8th will be paid a $0.20 dividend. The ex-dividend date is Tuesday, May 7th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 3.89%.

Analyst Upgrades and Downgrades

Several research firms have commented on KVUE. HSBC boosted their price target on shares of Kenvue from $20.00 to $21.00 and gave the stock a “hold” rating in a report on Wednesday. William Blair started coverage on Kenvue in a research note on Wednesday, April 3rd. They issued a “market perform” rating on the stock. The Goldman Sachs Group began coverage on Kenvue in a report on Friday, March 1st. They issued a “neutral” rating and a $20.00 price objective on the stock. Royal Bank of Canada decreased their target price on Kenvue from $25.00 to $24.00 and set an “outperform” rating for the company in a research note on Friday, February 9th. Finally, JPMorgan Chase & Co. dropped their price target on shares of Kenvue from $25.00 to $24.00 and set an “overweight” rating on the stock in a research note on Friday, February 9th. One analyst has rated the stock with a sell rating, eight have given a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, Kenvue currently has a consensus rating of “Hold” and an average target price of $24.38.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.